Skip to main content
Top
Published in: Abdominal Radiology 7/2018

01-07-2018

Differentiating focal nodular hyperplasia from hepatocellular adenoma: Is hepatobiliary phase MRI (HBP-MRI) using linear gadolinium chelates always useful?

Authors: Marion Roux, Frederic Pigneur, Laurence Baranes, Julien Calderaro, Mélanie Chiaradia, Thomas Decaens, Sandrine Kastahian, Anaïs Charles-Nelson, Lambros Tselikas, Charlotte Costentin, Alexis Laurent, Daniel Azoulay, Ariane Mallat, Alain Rahmouni, Alain Luciani

Published in: Abdominal Radiology | Issue 7/2018

Login to get access

Abstract

Purpose

To assess the value of Hepatobiliary phase MRI (HPB-MRI) to differentiate FNH and HCA, and evaluate its impact on diagnostic accuracy, diagnostic confidence, inter-observer variability, and patient clinical management.

Methods

Forty-nine patients referred for Gd-BOPTA-enhanced MRI were retrospectively included in this IRB-approved study, with a total of 119 lesions—90 FNH and 29 HCA. Two observers separately assessed in 2 distinct randomized reading sessions the performance of MRI with (HBP-MRI) or without (conventional MRI) the use of HBP images. Each lesion was ranked with a 5-point scale (from 1 Typical FNH to 5 Certainly not a FNH). Sensitivity, specificity, overall accuracy, and inter-observer agreement for the differentiation of FNH from HCA were calculated and compared between conventional and HBP-MRI.

Results

Both sensitivity (respective values of 38.9% and 97.8%), overall accuracy (respective values of 53.8% and 98.3%), and inter-observer agreement (respective values of Kappa 0.56 and 0.88) were significantly higher using HBP-MRI than with conventional MRI, with unchanged specificity (100%). The sensitivity of conventional MRI for the diagnosis of FNH was significantly lower in lesions ≤ 3 cm (20% vs. 88%). Overall, HBP could have changed lesion management in 59/119 cases (49.5%), including 53 FNH and 6 HCA with no impact in 60/119 lesions (50.5%) including all 35 lesions classified as scores 1 and 2 for the diagnosis of FNH.

Conclusions

The clinical impact of HBP-MRI is mostly important for smaller than 3-cm FNH, and more limited in larger FNH lesions as well as for HCA diagnosis for which conventional MRI is already accurate. The use of extracellular contrast agents upfront could limit the required use of linear HBP contrast agents for benign hepatocellular lesion characterization. On HBP, all FNH appeared hypointense compared to adjacent liver while close to 97% of HCA appeared hypointense.
Literature
1.
go back to reference Nault JC, Bioulac-Sage P, Zucman-Rossi J (2013) Hepatocellular benign tumors-from molecular classification to personalized clinical care. Gastroenterology 144:888–902CrossRefPubMed Nault JC, Bioulac-Sage P, Zucman-Rossi J (2013) Hepatocellular benign tumors-from molecular classification to personalized clinical care. Gastroenterology 144:888–902CrossRefPubMed
2.
go back to reference Charny CK, Jarnagin WR, Schwartz LH, et al. (2001) Management of 155 patients with benign liver tumours. Br J Surg 88:808–813CrossRefPubMed Charny CK, Jarnagin WR, Schwartz LH, et al. (2001) Management of 155 patients with benign liver tumours. Br J Surg 88:808–813CrossRefPubMed
3.
go back to reference Shanbhogue AK, Prasad SR, Takahashi N, Vikram R, Sahani DV (2011) Recent advances in cytogenetics and molecular biology of adult hepatocellular tumors: implications for imaging and management. Radiology 258:673–693CrossRefPubMed Shanbhogue AK, Prasad SR, Takahashi N, Vikram R, Sahani DV (2011) Recent advances in cytogenetics and molecular biology of adult hepatocellular tumors: implications for imaging and management. Radiology 258:673–693CrossRefPubMed
4.
go back to reference Cherqui D, Rahmouni A, Charlotte F, et al. (1995) Management of focal nodular hyperplasia and hepatocellular adenoma in young women: a series of 41 patients with clinical, radiological, and pathological correlations. Hepatology 22:1674–1681CrossRefPubMed Cherqui D, Rahmouni A, Charlotte F, et al. (1995) Management of focal nodular hyperplasia and hepatocellular adenoma in young women: a series of 41 patients with clinical, radiological, and pathological correlations. Hepatology 22:1674–1681CrossRefPubMed
5.
go back to reference Ferlicot S, Kobeiter H, Tran Van Nhieu J, et al. (2004) MRI of atypical focal nodular hyperplasia of the liver: radiology-pathology correlation. AJR Am J Roentgenol 182:1227–1231CrossRefPubMed Ferlicot S, Kobeiter H, Tran Van Nhieu J, et al. (2004) MRI of atypical focal nodular hyperplasia of the liver: radiology-pathology correlation. AJR Am J Roentgenol 182:1227–1231CrossRefPubMed
6.
go back to reference Ronot M, Vilgrain V (2014) Imaging of benign hepatocellular lesions: current concepts and recent updates. Clin Res Hepatol Gastroenterol 38:681–688CrossRefPubMed Ronot M, Vilgrain V (2014) Imaging of benign hepatocellular lesions: current concepts and recent updates. Clin Res Hepatol Gastroenterol 38:681–688CrossRefPubMed
7.
go back to reference Ba-Ssalamah A, Schima W, Schmook MT, et al. (2002) Atypical focal nodular hyperplasia of the liver: imaging features of nonspecific and liver-specific MR contrast agents. AJR Am J Roentgenol 179:1447–1456CrossRefPubMed Ba-Ssalamah A, Schima W, Schmook MT, et al. (2002) Atypical focal nodular hyperplasia of the liver: imaging features of nonspecific and liver-specific MR contrast agents. AJR Am J Roentgenol 179:1447–1456CrossRefPubMed
8.
go back to reference Neri E, Bali MA, Ba-Ssalamah A, et al. (2016) ESGAR consensus statement on liver MR imaging and clinical use of liver-specific contrast agents. Eur Radiol 26:921–931CrossRefPubMed Neri E, Bali MA, Ba-Ssalamah A, et al. (2016) ESGAR consensus statement on liver MR imaging and clinical use of liver-specific contrast agents. Eur Radiol 26:921–931CrossRefPubMed
9.
go back to reference Roche V, Pigneur F, Tselikas L, et al. (2015) Differentiation of focal nodular hyperplasia from hepatocellular adenomas with low-mechanical-index contrast-enhanced sonography (CEUS): effect of size on diagnostic confidence. Eur Radiol 25:186–195CrossRefPubMed Roche V, Pigneur F, Tselikas L, et al. (2015) Differentiation of focal nodular hyperplasia from hepatocellular adenomas with low-mechanical-index contrast-enhanced sonography (CEUS): effect of size on diagnostic confidence. Eur Radiol 25:186–195CrossRefPubMed
10.
go back to reference Millet P, Moulin M, Stieger B, Daali Y, Pastor CM (2011) How organic anions accumulate in hepatocytes lacking Mrp2: evidence in rat liver. J Pharmacol Exp Ther 336:624–632CrossRefPubMed Millet P, Moulin M, Stieger B, Daali Y, Pastor CM (2011) How organic anions accumulate in hepatocytes lacking Mrp2: evidence in rat liver. J Pharmacol Exp Ther 336:624–632CrossRefPubMed
11.
go back to reference Pastor CM (2010) Gadoxetic acid-enhanced hepatobiliary phase MR imaging: cellular insight. Radiology 257:589CrossRefPubMed Pastor CM (2010) Gadoxetic acid-enhanced hepatobiliary phase MR imaging: cellular insight. Radiology 257:589CrossRefPubMed
12.
go back to reference Pastor CM, Planchamp C, Pochon S, et al. (2003) Kinetics of gadobenate dimeglumine in isolated perfused rat liver: MR imaging evaluation. Radiology 229:119–125CrossRefPubMed Pastor CM, Planchamp C, Pochon S, et al. (2003) Kinetics of gadobenate dimeglumine in isolated perfused rat liver: MR imaging evaluation. Radiology 229:119–125CrossRefPubMed
13.
go back to reference Planchamp C, Hadengue A, Stieger B, et al. (2007) Function of both sinusoidal and canalicular transporters controls the concentration of organic anions within hepatocytes. Mol Pharmacol 71:1089–1097CrossRefPubMed Planchamp C, Hadengue A, Stieger B, et al. (2007) Function of both sinusoidal and canalicular transporters controls the concentration of organic anions within hepatocytes. Mol Pharmacol 71:1089–1097CrossRefPubMed
14.
go back to reference de Haen C, Lorusso V, Luzzani F, Tirone P (1995) Hepatic transport of the magnetic resonance imaging contrast agent gadobenate dimeglumine in the rat. Acad Radiol 2:232–238CrossRefPubMed de Haen C, Lorusso V, Luzzani F, Tirone P (1995) Hepatic transport of the magnetic resonance imaging contrast agent gadobenate dimeglumine in the rat. Acad Radiol 2:232–238CrossRefPubMed
15.
go back to reference Spinazzi A, Lorusso V, Pirovano G, Kirchin M (1999) Safety, tolerance, biodistribution, and MR imaging enhancement of the liver with gadobenate dimeglumine: results of clinical pharmacologic and pilot imaging studies in nonpatient and patient volunteers. Acad Radiol 6:282–291CrossRefPubMed Spinazzi A, Lorusso V, Pirovano G, Kirchin M (1999) Safety, tolerance, biodistribution, and MR imaging enhancement of the liver with gadobenate dimeglumine: results of clinical pharmacologic and pilot imaging studies in nonpatient and patient volunteers. Acad Radiol 6:282–291CrossRefPubMed
16.
17.
go back to reference Brismar TB, Dahlstrom N, Edsborg N, et al. (2009) Liver vessel enhancement by Gd-BOPTA and Gd-EOB-DTPA: a comparison in healthy volunteers. Acta Radiol 50:709–715CrossRefPubMed Brismar TB, Dahlstrom N, Edsborg N, et al. (2009) Liver vessel enhancement by Gd-BOPTA and Gd-EOB-DTPA: a comparison in healthy volunteers. Acta Radiol 50:709–715CrossRefPubMed
18.
go back to reference Dahlqvist Leinhard O, Dahlstrom N, Kihlberg J, et al. (2012) Quantifying differences in hepatic uptake of the liver specific contrast agents Gd-EOB-DTPA and Gd-BOPTA: a pilot study. Eur Radiol 22:642–653CrossRefPubMed Dahlqvist Leinhard O, Dahlstrom N, Kihlberg J, et al. (2012) Quantifying differences in hepatic uptake of the liver specific contrast agents Gd-EOB-DTPA and Gd-BOPTA: a pilot study. Eur Radiol 22:642–653CrossRefPubMed
19.
go back to reference Runge VM (1998) A comparison of two MR hepatobiliary gadolinium chelates: Gd-BOPTA and Gd-EOB-DTPA. J Comput Assist Tomogr 22:643–650CrossRefPubMed Runge VM (1998) A comparison of two MR hepatobiliary gadolinium chelates: Gd-BOPTA and Gd-EOB-DTPA. J Comput Assist Tomogr 22:643–650CrossRefPubMed
20.
go back to reference Bieze M, van den Esschert JW, Nio CY, et al. (2012) Diagnostic accuracy of MRI in differentiating hepatocellular adenoma from focal nodular hyperplasia: prospective study of the additional value of gadoxetate disodium. AJR Am J Roentgenol 199:26–34CrossRefPubMed Bieze M, van den Esschert JW, Nio CY, et al. (2012) Diagnostic accuracy of MRI in differentiating hepatocellular adenoma from focal nodular hyperplasia: prospective study of the additional value of gadoxetate disodium. AJR Am J Roentgenol 199:26–34CrossRefPubMed
21.
go back to reference Grazioli L, Morana G, Federle MP, et al. (2001) Focal nodular hyperplasia: morphologic and functional information from MR imaging with gadobenate dimeglumine. Radiology 221:731–739CrossRefPubMed Grazioli L, Morana G, Federle MP, et al. (2001) Focal nodular hyperplasia: morphologic and functional information from MR imaging with gadobenate dimeglumine. Radiology 221:731–739CrossRefPubMed
22.
go back to reference Grazioli L, Morana G, Kirchin MA, Schneider G (2005) Accurate differentiation of focal nodular hyperplasia from hepatic adenoma at gadobenate dimeglumine-enhanced MR imaging: prospective study. Radiology 236:166–177CrossRefPubMed Grazioli L, Morana G, Kirchin MA, Schneider G (2005) Accurate differentiation of focal nodular hyperplasia from hepatic adenoma at gadobenate dimeglumine-enhanced MR imaging: prospective study. Radiology 236:166–177CrossRefPubMed
23.
go back to reference McInnes MD, Hibbert RM, Inacio JR, Schieda N (2015) Focal nodular hyperplasia and hepatocellular adenoma: accuracy of gadoxetic acid-enhanced MR imaging-A systematic review. Radiology 277:927CrossRefPubMed McInnes MD, Hibbert RM, Inacio JR, Schieda N (2015) Focal nodular hyperplasia and hepatocellular adenoma: accuracy of gadoxetic acid-enhanced MR imaging-A systematic review. Radiology 277:927CrossRefPubMed
24.
go back to reference Pirovano G, Vanzulli A, Marti-Bonmati L, et al. (2000) Evaluation of the accuracy of gadobenate dimeglumine-enhanced MR imaging in the detection and characterization of focal liver lesions. AJR Am J Roentgenol 175:1111–1120CrossRefPubMed Pirovano G, Vanzulli A, Marti-Bonmati L, et al. (2000) Evaluation of the accuracy of gadobenate dimeglumine-enhanced MR imaging in the detection and characterization of focal liver lesions. AJR Am J Roentgenol 175:1111–1120CrossRefPubMed
25.
go back to reference Purysko AS, Remer EM, Coppa CP, et al. (2012) Characteristics and distinguishing features of hepatocellular adenoma and focal nodular hyperplasia on gadoxetate disodium-enhanced MRI. AJR Am J Roentgenol 198:115–123CrossRefPubMed Purysko AS, Remer EM, Coppa CP, et al. (2012) Characteristics and distinguishing features of hepatocellular adenoma and focal nodular hyperplasia on gadoxetate disodium-enhanced MRI. AJR Am J Roentgenol 198:115–123CrossRefPubMed
26.
go back to reference Agarwal S, Fuentes-Orrego JM, Arnason T, et al. (2014) Inflammatory hepatocellular adenomas can mimic focal nodular hyperplasia on gadoxetic acid-enhanced MRI. AJR Am J Roentgenol 203:W408–W414CrossRefPubMed Agarwal S, Fuentes-Orrego JM, Arnason T, et al. (2014) Inflammatory hepatocellular adenomas can mimic focal nodular hyperplasia on gadoxetic acid-enhanced MRI. AJR Am J Roentgenol 203:W408–W414CrossRefPubMed
27.
go back to reference Grazioli L, Bondioni MP, Haradome H, et al. (2012) Hepatocellular adenoma and focal nodular hyperplasia: value of gadoxetic acid-enhanced MR imaging in differential diagnosis. Radiology 262:520–529CrossRefPubMed Grazioli L, Bondioni MP, Haradome H, et al. (2012) Hepatocellular adenoma and focal nodular hyperplasia: value of gadoxetic acid-enhanced MR imaging in differential diagnosis. Radiology 262:520–529CrossRefPubMed
29.
go back to reference Suh CH, Kim KW, Kim GY, et al. (2015) The diagnostic value of Gd-EOB-DTPA-MRI for the diagnosis of focal nodular hyperplasia: a systematic review and meta-analysis. Eur Radiol 25:950–960CrossRefPubMed Suh CH, Kim KW, Kim GY, et al. (2015) The diagnostic value of Gd-EOB-DTPA-MRI for the diagnosis of focal nodular hyperplasia: a systematic review and meta-analysis. Eur Radiol 25:950–960CrossRefPubMed
30.
go back to reference Zech CJ, Grazioli L, Breuer J, Reiser MF, Schoenberg SO (2008) Diagnostic performance and description of morphological features of focal nodular hyperplasia in Gd-EOB-DTPA-enhanced liver magnetic resonance imaging: results of a multicenter trial. Invest Radiol 43:504–511CrossRefPubMed Zech CJ, Grazioli L, Breuer J, Reiser MF, Schoenberg SO (2008) Diagnostic performance and description of morphological features of focal nodular hyperplasia in Gd-EOB-DTPA-enhanced liver magnetic resonance imaging: results of a multicenter trial. Invest Radiol 43:504–511CrossRefPubMed
31.
go back to reference Quaia E (2012) Solid focal liver lesions indeterminate by contrast-enhanced CT or MR imaging: the added diagnostic value of contrast-enhanced ultrasound. Abdom Imaging 37:580–590CrossRefPubMed Quaia E (2012) Solid focal liver lesions indeterminate by contrast-enhanced CT or MR imaging: the added diagnostic value of contrast-enhanced ultrasound. Abdom Imaging 37:580–590CrossRefPubMed
32.
go back to reference Robert P, Violas X, Grand S, et al. (2016) Linear gadolinium-based contrast agents are associated with brain gadolinium retention in healthy rats. Invest Radiol 51:73–82CrossRefPubMedPubMedCentral Robert P, Violas X, Grand S, et al. (2016) Linear gadolinium-based contrast agents are associated with brain gadolinium retention in healthy rats. Invest Radiol 51:73–82CrossRefPubMedPubMedCentral
34.
go back to reference Kanda T, Ishii K, Kawaguchi H, Kitajima K, Takenaka D (2014) High signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted MR images: relationship with increasing cumulative dose of a gadolinium-based contrast material. Radiology 270:834–841CrossRefPubMed Kanda T, Ishii K, Kawaguchi H, Kitajima K, Takenaka D (2014) High signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted MR images: relationship with increasing cumulative dose of a gadolinium-based contrast material. Radiology 270:834–841CrossRefPubMed
35.
go back to reference Radbruch A, Weberling LD, Kieslich PJ, et al. (2015) Gadolinium retention in the dentate nucleus and globus pallidus is dependent on the class of contrast agent. Radiology 275:783–791CrossRefPubMed Radbruch A, Weberling LD, Kieslich PJ, et al. (2015) Gadolinium retention in the dentate nucleus and globus pallidus is dependent on the class of contrast agent. Radiology 275:783–791CrossRefPubMed
36.
go back to reference Runge VM (2017) Critical questions regarding gadolinium deposition in the brain and body after injections of the gadolinium-based contrast agents, safety, and clinical recommendations in consideration of the EMA’s pharmacovigilance and risk assessment committee recommendation for suspension of the marketing authorizations for 4 linear agents. Invest Radiol 52:317–323CrossRefPubMed Runge VM (2017) Critical questions regarding gadolinium deposition in the brain and body after injections of the gadolinium-based contrast agents, safety, and clinical recommendations in consideration of the EMA’s pharmacovigilance and risk assessment committee recommendation for suspension of the marketing authorizations for 4 linear agents. Invest Radiol 52:317–323CrossRefPubMed
38.
go back to reference Bioulac-Sage P, Laumonier H, Couchy G, et al. (2009) Hepatocellular adenoma management and phenotypic classification: the Bordeaux experience. Hepatology 50:481–489CrossRefPubMed Bioulac-Sage P, Laumonier H, Couchy G, et al. (2009) Hepatocellular adenoma management and phenotypic classification: the Bordeaux experience. Hepatology 50:481–489CrossRefPubMed
39.
go back to reference Zucman-Rossi J, Jeannot E, Nhieu JT, et al. (2006) Genotype-phenotype correlation in hepatocellular adenoma: new classification and relationship with HCC. Hepatology 43:515–524CrossRefPubMed Zucman-Rossi J, Jeannot E, Nhieu JT, et al. (2006) Genotype-phenotype correlation in hepatocellular adenoma: new classification and relationship with HCC. Hepatology 43:515–524CrossRefPubMed
40.
go back to reference Bioulac-Sage P, Balabaud C, Zucman-Rossi J (2010) Subtype classification of hepatocellular adenoma. Dig Surg 27:39–45CrossRefPubMed Bioulac-Sage P, Balabaud C, Zucman-Rossi J (2010) Subtype classification of hepatocellular adenoma. Dig Surg 27:39–45CrossRefPubMed
41.
go back to reference Bioulac-Sage P, Blanc JF, Rebouissou S, Balabaud C, Zucman-Rossi J (2007) Genotype phenotype classification of hepatocellular adenoma. World J Gastroenterol 13:2649–2654CrossRefPubMedPubMedCentral Bioulac-Sage P, Blanc JF, Rebouissou S, Balabaud C, Zucman-Rossi J (2007) Genotype phenotype classification of hepatocellular adenoma. World J Gastroenterol 13:2649–2654CrossRefPubMedPubMedCentral
42.
go back to reference Cristiano A, Dietrich A, Spina JC, Ardiles V, de Santibanes E (2014) Focal nodular hyperplasia and hepatic adenoma: current diagnosis and management. Updates Surg 66:9–21CrossRefPubMed Cristiano A, Dietrich A, Spina JC, Ardiles V, de Santibanes E (2014) Focal nodular hyperplasia and hepatic adenoma: current diagnosis and management. Updates Surg 66:9–21CrossRefPubMed
43.
go back to reference van den Esschert JW, van Gulik TM, Phoa SS (2010) Imaging modalities for focal nodular hyperplasia and hepatocellular adenoma. Dig Surg 27:46–55CrossRefPubMed van den Esschert JW, van Gulik TM, Phoa SS (2010) Imaging modalities for focal nodular hyperplasia and hepatocellular adenoma. Dig Surg 27:46–55CrossRefPubMed
44.
go back to reference Mathieu D, Rahmouni A, Anglade MC, et al. (1991) Focal nodular hyperplasia of the liver: assessment with contrast-enhanced TurboFLASH MR imaging. Radiology 180:25–30CrossRefPubMed Mathieu D, Rahmouni A, Anglade MC, et al. (1991) Focal nodular hyperplasia of the liver: assessment with contrast-enhanced TurboFLASH MR imaging. Radiology 180:25–30CrossRefPubMed
45.
go back to reference Vilgrain V, Flejou JF, Arrive L, et al. (1992) Focal nodular hyperplasia of the liver: MR imaging and pathologic correlation in 37 patients. Radiology 184:699–703CrossRefPubMed Vilgrain V, Flejou JF, Arrive L, et al. (1992) Focal nodular hyperplasia of the liver: MR imaging and pathologic correlation in 37 patients. Radiology 184:699–703CrossRefPubMed
46.
go back to reference Chung KY, Mayo-Smith WW, Saini S, et al. (1995) Hepatocellular adenoma: MR imaging features with pathologic correlation. AJR Am J Roentgenol 165:303–308CrossRefPubMed Chung KY, Mayo-Smith WW, Saini S, et al. (1995) Hepatocellular adenoma: MR imaging features with pathologic correlation. AJR Am J Roentgenol 165:303–308CrossRefPubMed
47.
go back to reference Laumonier H, Bioulac-Sage P, Laurent C, et al. (2008) Hepatocellular adenomas: magnetic resonance imaging features as a function of molecular pathological classification. Hepatology 48:808–818CrossRefPubMed Laumonier H, Bioulac-Sage P, Laurent C, et al. (2008) Hepatocellular adenomas: magnetic resonance imaging features as a function of molecular pathological classification. Hepatology 48:808–818CrossRefPubMed
48.
go back to reference Merkle EM, Zech CJ, Bartolozzi C, et al. (2016) Consensus report from the 7th international forum for liver magnetic resonance imaging. Eur Radiol 26:674–682CrossRefPubMed Merkle EM, Zech CJ, Bartolozzi C, et al. (2016) Consensus report from the 7th international forum for liver magnetic resonance imaging. Eur Radiol 26:674–682CrossRefPubMed
49.
go back to reference Kim HJ, Kim BS, Kim MJ, et al. (2013) Enhancement of the liver and pancreas in the hepatic arterial dominant phase: comparison of hepatocyte-specific MRI contrast agents, gadoxetic acid and gadobenate dimeglumine, on 3 and 1.5 Tesla MRI in the same patient. J Magn Reson Imaging 37:903–908CrossRefPubMed Kim HJ, Kim BS, Kim MJ, et al. (2013) Enhancement of the liver and pancreas in the hepatic arterial dominant phase: comparison of hepatocyte-specific MRI contrast agents, gadoxetic acid and gadobenate dimeglumine, on 3 and 1.5 Tesla MRI in the same patient. J Magn Reson Imaging 37:903–908CrossRefPubMed
50.
51.
go back to reference Landis JR, Koch GG (1977) The measurement of observer agreement for categorical data. Biometrics 33:159–174CrossRefPubMed Landis JR, Koch GG (1977) The measurement of observer agreement for categorical data. Biometrics 33:159–174CrossRefPubMed
52.
go back to reference Thomeer MG, Willemssen FE, Biermann KK, et al. (2014) MRI features of inflammatory hepatocellular adenomas on hepatocyte phase imaging with liver-specific contrast agents. J Magn Reson Imaging 39:1259–1264CrossRefPubMed Thomeer MG, Willemssen FE, Biermann KK, et al. (2014) MRI features of inflammatory hepatocellular adenomas on hepatocyte phase imaging with liver-specific contrast agents. J Magn Reson Imaging 39:1259–1264CrossRefPubMed
53.
go back to reference Tse JR, Naini BV, Lu DS, Raman SS (2016) Qualitative and quantitative gadoxetic acid-enhanced MR imaging helps subtype hepatocellular adenomas. Radiology 279:118–127CrossRefPubMed Tse JR, Naini BV, Lu DS, Raman SS (2016) Qualitative and quantitative gadoxetic acid-enhanced MR imaging helps subtype hepatocellular adenomas. Radiology 279:118–127CrossRefPubMed
54.
go back to reference Gupta RT, Iseman CM, Leyendecker JR, et al. (2012) Diagnosis of focal nodular hyperplasia with MRI: multicenter retrospective study comparing gadobenate dimeglumine to gadoxetate disodium. AJR Am J Roentgenol 199:35–43CrossRefPubMed Gupta RT, Iseman CM, Leyendecker JR, et al. (2012) Diagnosis of focal nodular hyperplasia with MRI: multicenter retrospective study comparing gadobenate dimeglumine to gadoxetate disodium. AJR Am J Roentgenol 199:35–43CrossRefPubMed
55.
go back to reference Davenport MS, Caoili EM, Kaza RK, Hussain HK (2014) Matched within-patient cohort study of transient arterial phase respiratory motion-related artifact in MR imaging of the liver: gadoxetate disodium versus gadobenate dimeglumine. Radiology 272:123–131CrossRefPubMed Davenport MS, Caoili EM, Kaza RK, Hussain HK (2014) Matched within-patient cohort study of transient arterial phase respiratory motion-related artifact in MR imaging of the liver: gadoxetate disodium versus gadobenate dimeglumine. Radiology 272:123–131CrossRefPubMed
56.
go back to reference Davenport MS, Viglianti BL, Al-Hawary MM, et al. (2013) Comparison of acute transient dyspnea after intravenous administration of gadoxetate disodium and gadobenate dimeglumine: effect on arterial phase image quality. Radiology 266:452–461CrossRefPubMed Davenport MS, Viglianti BL, Al-Hawary MM, et al. (2013) Comparison of acute transient dyspnea after intravenous administration of gadoxetate disodium and gadobenate dimeglumine: effect on arterial phase image quality. Radiology 266:452–461CrossRefPubMed
57.
go back to reference Luciani A, Kobeiter H, Maison P, et al. (2002) Focal nodular hyperplasia of the liver in men: is presentation the same in men and women? Gut 50:877–880CrossRefPubMedPubMedCentral Luciani A, Kobeiter H, Maison P, et al. (2002) Focal nodular hyperplasia of the liver in men: is presentation the same in men and women? Gut 50:877–880CrossRefPubMedPubMedCentral
58.
go back to reference Grazioli L, Morana G, Caudana R, et al. (2000) Hepatocellular carcinoma: correlation between gadobenate dimeglumine-enhanced MRI and pathologic findings. Invest Radiol 35:25–34CrossRefPubMed Grazioli L, Morana G, Caudana R, et al. (2000) Hepatocellular carcinoma: correlation between gadobenate dimeglumine-enhanced MRI and pathologic findings. Invest Radiol 35:25–34CrossRefPubMed
59.
go back to reference Hwang HS, Kim SH, Jeon TY, et al. (2009) Hypointense hepatic lesions depicted on gadobenate dimeglumine-enhanced three-hour delayed hepatobiliary-phase MR imaging: differentiation between benignancy and malignancy. Korean J Radiol 10:294–302CrossRefPubMedPubMedCentral Hwang HS, Kim SH, Jeon TY, et al. (2009) Hypointense hepatic lesions depicted on gadobenate dimeglumine-enhanced three-hour delayed hepatobiliary-phase MR imaging: differentiation between benignancy and malignancy. Korean J Radiol 10:294–302CrossRefPubMedPubMedCentral
60.
go back to reference Yoneda N, Matsui O, Kitao A, et al. (2012) Beta-catenin-activated hepatocellular adenoma showing hyperintensity on hepatobiliary-phase gadoxetic-enhanced magnetic resonance imaging and overexpression of OATP8. Jpn J Radiol 30:777–782CrossRefPubMed Yoneda N, Matsui O, Kitao A, et al. (2012) Beta-catenin-activated hepatocellular adenoma showing hyperintensity on hepatobiliary-phase gadoxetic-enhanced magnetic resonance imaging and overexpression of OATP8. Jpn J Radiol 30:777–782CrossRefPubMed
Metadata
Title
Differentiating focal nodular hyperplasia from hepatocellular adenoma: Is hepatobiliary phase MRI (HBP-MRI) using linear gadolinium chelates always useful?
Authors
Marion Roux
Frederic Pigneur
Laurence Baranes
Julien Calderaro
Mélanie Chiaradia
Thomas Decaens
Sandrine Kastahian
Anaïs Charles-Nelson
Lambros Tselikas
Charlotte Costentin
Alexis Laurent
Daniel Azoulay
Ariane Mallat
Alain Rahmouni
Alain Luciani
Publication date
01-07-2018
Publisher
Springer US
Published in
Abdominal Radiology / Issue 7/2018
Print ISSN: 2366-004X
Electronic ISSN: 2366-0058
DOI
https://doi.org/10.1007/s00261-017-1377-z

Other articles of this Issue 7/2018

Abdominal Radiology 7/2018 Go to the issue